Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594333 · ClinicalTrials.gov registry record · Phase 3
Cardiovascular Inflammation Reduction Trial
A Phase 3 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,786
- Enrollment target
NCT01594333: Completed Phase 3 study, sponsored by Brigham and Women's Hospital.
NCT01594333 is a Phase 3 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4,786 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (520% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01594333, a Phase 3 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,786 participants
- Enrollment target
Study Summary
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Primary Outcome
The first occurrence of Major Adverse Cardiovascular Event which is defined as the occurrence of one or more of the following: Cardiovascular Death, Non-Fatal Myocardial Infarction or Non-Fatal Stroke.
Interventions
- DRUG Placebo
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,786 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 3 |
What the finished NCT01594333 record still lists
NCT01594333 is an interventional study that assigns participants to a tested intervention. Its 4,786 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (520% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01594333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01594333 about?
NCT01594333 is a clinical study titled "Cardiovascular Inflammation Reduction Trial". The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This tri...
What is the current status of trial NCT01594333?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,786 participants. The study started on 2013-04. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT01594333?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01594333?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01594333's enrollment target sits among peer trials
4,786 54th of 2000 higher than 1,947 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
- NCT06307652 · 4,800 participants · Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia